Knappschaft Kliniken
Universitätsklinikum Bochum

Es werden mehrere klinische und experimentelle Forschungsprojekte bearbeitet:

Seidel S, Wehner T, Miller D, Wellmer J, Schlegel U, Grönheit W. Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication. Neurol Res Pract. 2022 Sep 5;4(1):45. doi: 10.1186/s42466-022-00205-9. PMID: 36059029; PMCID: PMC9442934.

Seidel S, Kowalski T, Nilius-Eliliwi V, Schroers R, Schlegel U. Outcome and prognostic factors of very old patients with primary CNS lymphoma: a retrospective analysis of patients ≥80 years treated with high-dosmethotrexate-based chemotherapy. Leuk Lymphoma. 2022 Jul 20:1-7. doi: 10.1080/10428194.2022.2100371. Epub ahead of print. PMID: 35856480

Seidel S, Nilius-Eliliwi V, Kowalski T, Vangala DB, Schlegel U, Schroers R. High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Primary CNS Lymphoma: A Retrospective Monocentric Analysis of Long-Term Outcome, Prognostic Factors, and Toxicity. Cancers (Basel). 2022 Apr 23;14(9):2100. doi: 10.3390/cancers14092100. PMID: 35565230;PMCID: PMC9106040.

Margold M, Seidel S, Kowalski T, Ladigan-Badura S, Baraniskin A, Schroers R, Frey AV, Schmidt-Wolf IGH, Herrlinger U, Korfel A, Schlegel U. The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. Neuro Oncol.
2021 Dec 1;23(12):2076-2084. doi: 10.1093/neuonc/noab109. PMID: 33984138; PMCID: PMC8643483.

Seidel S, Margold M, Kowalski T, Baraniskin A, Schroers R, Korfel A, Thiel E, Weller M, Martus P, Schlegel U. Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome. Cancers (Basel). 2021 Jun 11;13(12):2934. doi: 10.3390/cancers13122934.
PMID: 34208229; PMCID: PMC8230869.
Pertz M, Kowalski T, Schlegel U, Thoma P. Mental time travel in patients "cured" from primary central nervous system lymphoma J Clin Exp Neuropsychol. 2021 Apr;43(3):264

Pertz M, Kowalski T, Thoma P, Schlegel U. What Is on Your Mind? Impaired Social Cognition in Primary Central Nervous System Lymphoma Patients Despite Ongoing Complete Remission. Cancers (Basel). 2021 Feb 24;13(5):943

Gramatzki D, Felsberg J, Hentschel B, Wolter M, Schackert G, Westphal M, Regli L, Thon N, Tatagiba M, Wick W, Schlegel U, Krex D, Matschke J, Roth P, Suresh MP, Kamp MA, Rushing EJ, Pietsch T, von Deimling A, Sabel M, Loeffler M, Weller M, Reifenberger G. Telomerase reverse transcriptase promotor mutation- and O6-methylgguanine DNA methyltransferase promotor methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? J. Cancer 2021;PMID:33631540 Free article

Tzaridis T, Schäfer N, Weller J, Steinbach JP, Schlegel U, Seidel S, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Tonn JC, Grauer O, Kebir S, Schneider M, Schaub C, Vatter H, Coch C, Glas M, Fimmers R, Pietsch T, Reifenberg G, Herrlinger U, Felsberg J. MGMT promotor methylation analysis for allocating combined CCNU/TMZ chemotherapy: lessons learned from the CeTeG/NOA-09- trial. Int J Cancer. 2021;148: 1965 - 1707

Pertz M, Kowalski T, Thoma P, Schlegel U. What is on your mind? Impaired social cognition in primary central nervous system lymphoma patients despite ongoing complete remission. Cancers (Basel) 2021;13: 943

Anton S, Margold M, Kowalski T, Miller D, Schmieder K, Schlegel U, Seidel S. Complications of intracerebroventricular chemotherapy via subgaleal reservoir in primary central nervous system lymphoma: a single-institution experience on 1247 installations in 94 consecutive patients. Hematol Oncol.2020. PMID: 33307466

Seidel S, Pels H, Schlömer S, Kowoll A, Fliessbach K, Engert A, Vogt-Schaden M, Egerer G, Reichmann H, Schackert G, Kroschinsky F, Deckert M, Herrlinger U, Klockgether T, Fimmers R, Bode U, Schmidt-Wolf I, Schlegel U. Twenty years follow-up of a pilot/phase II-trial on the Bonn protocol for primary CNS lymphoma. Neurology 2020;95: e3138 – e3144

Seidel S, Kowalski T, Margold M, Baraniskin A, Schroers R, Martus P, Schlegel U. HDMTX-based polychemotherapy including intraventricular therapy in elderly patients with primaryCNS lymphoma: A single center series. Ther Adv Neurol Disord 2020;13: 1756286420951087

Waldera-Lupa DM, Poschmann G, Kirchgaessler N, Etemad-Parishanzadeh O,, Baberg F, Brocksieper M, Seidel S, Kowalski T, Brunn A, Haghikia a, Gold R, Stefanski A, Deckert M, Schlegel U, Stühler K. A multiplex assay for the stratification of patients with primary Central Nervous Lymphoma using targeted mass spectrometry. Cancers (Basel) 2020;10: E1732.doi:

Wiemann G, Pertz M, Kowalski T, Seidel S, Schlegel U, Thoma P. Complete response to therapy: why do primary central nervous system lymphoma patients not return to work? J Neurooncol. 2020;doi: 10.1007/s11060-020-03587-5. Online ahead of print.

Waldera-Lupa DM, Poschmann G, Kirchgaessler N, Etemad-Parishanzadeh O, Baberg F, Brocksieper M, Seidel S, Kowalski T, Brunn A, Haghikia A, Gold R, Stefanski A, Deckert M, Schlegel U, Stühler K. A multiplex assay for the stratification of patients with primary Central Nervous System Lymphoma using targeted mass spectrometry. Cancers (Basel) 2020;12: EE1732.doi:

Pertz M, Popkirov S, Schlegel U, Thoma P. Research on cognitive and sociocognitive functions in patients with brain tumors: a bibliometric analysis and visualization of the scientific landscape. Neurol Sci 2020;Epub Feb 2020

Pertz M, Okoniewski A, Schlegel U, Thoma P. Impairment of sociocognitive functions in patients with brain tumours. Neuroscience and Biobehavioral Reviews 2020;108: 370–392

Seidel S, Korfel A, Kowalski T, Margold M, Ismail F, Schroers R, Baraniskin A, Pels H, Martus P, Schlegel U. HDMTX-based induction therapy followed by consolidation with conventional systemic chemotherapy and intraventricular therapy (modified Bonn protocol) in primary CNS lymphoma: a monocentric retrospectiv analysis. Neurol. Res. Pract. 2019;1:17

Seidel S, Schlegel U. Have treatment protocols for primary CNS lymphoma advanced in the past 10 years. Expert Rev Anticancer Ther. 2019;19: 909 - 915

Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2019;20: 1444 - 1453

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients oft he GLARIUS trial. J Neurooncol. 2019;144: 501 - 509

Binder H, Willscher E, Loeffler-Wirth H, Hopp L, Jones DTW, Pfister SM, Kreuz M, Gramatzki D, Fortenbacher E, Hentschel B, Tatagiba M, Herrlinger U, Vatter H, Matschke J, Westpfahl M, Krex D, Schackert G, Tonn JC, Schlegel U, Steiger HJ, Wick W, Weber RG, Weller M, Loeffler M. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development. Acta Neuropathol Commun. 2019;7: 59

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyenbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczny P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M, Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promotor (CeTeG/NOA 09): a randomized, open-label, phase 3 trial. Lancet 2019;393: 678 - 688

Beier D, Proescholt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortman RD, Bogdahn U, Hau P. Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medullablastoma (NOA-07). Neuro Oncol. 2018;20: 400 - 410

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, HÄnel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgreb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 2018;20: 975 - 985

Schlegel U, Korfel A. Is whole-brain radiotherapy still a standard treatment for primary central nervous system lymphomas? Curr Opin Neurol. 2018;31: 733 - 739

Von Baumgarten L, Illerhaus G, Korfel A, Schlegel U, Deckert M, Dreyling M. The diagnosis and treatment of Primary CNS Lymphoma. Dtsch. Ärzteblatt 2018;419 - 426

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkochzy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of lifee in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 2018;975 - 985

Baraniskin A, Chomiak M, Ahle G, Gress T, Buchholz M, Turewicz M, Eisenacher M, Margold M, Schlegel U, Schmiegel W, Hahn S, Schroers R. Micro-RNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma oft he CNS. J Neurooncol. 2018;137:463 - 468

Dagmar D, Proescholt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortman RD, Bogdahn U, Hau P. Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medullablastoma (NOA-07). Neuro Oncol. 2018;20: 400 - 410

Kowalski C, Graeven U, von Kalle C, Lang H, Beckmann MW, Blohmer JU, Burchardt M, Ehrenfeld M, Fichtner J, Grabbe S, Hoffman H, Iro H, Post S, Scharl A, Schlegel U, Seufferlein T, Stummer W, Ukena D, Ferencz J, Wesselmann S. Shifting cancer care towards multidisciplinarity: the cancer center certification program of the German cancer center society. BMC Cancer 2017;17: 850

Waldera-Lupa DM, Etemad-Parishanzadeh O, Brocksieper M, Kirchgaessler N, Seidel S, Kowalski T, Montesinos-Rongen M, Deckert M, Schlegel U, Stühler K. Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding. Oncotarget. 2017;8

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro Oncol 2017;[Epub ahead of print]

Gramatzki D, Kickingereder P, Hentschel B, Felsberg J, Herrlinger U, Schackert G, Tonn JC, Westphal M, Sabel M, Schlegel U,Wick W, Pietsch T, Reifenberger G, Loeffler M, Bendszus M, Weller M. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology 2017;88: 1422 – 1430

Kakkassery V, Schroers R, Coupland SE, Wunderlich MI, Schargus M, Heinz C, Wasmuth S, Heiligenhaus A, Ahle G, Lenoble P, Schlegel U, Schmiegel W, Dick HB, Baraniskin A. Vitreous microRNA levels as diagnostic biomarkers for vitreo-retinal lymphoma. Blood 2017;129: 3130 - 3133

Ismail SF, Schlegel U, Kowoll A, Skodda S. Episodic central hypopnea and hypotension: Caused by bleeding into a craniocervical ependymoma. Nervenarzt 2017;[Epub ahead of print].

Schlegel U, Korfel A. The challenge of adequate imaging surveillance in primary central nervous system lymphoma. Neuro Oncol. 2017;19: 307 - 308

Strehlow F, Bauer S, Martus P, Weller M, Roth P, Schlegel U, Seidel S, Scheibenbogen C, Korfel A, Kreher S. Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma. J Neuro-Oncol 2016;126: 165 - 171

Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnala S, Dai C, Ozawa T, Chang M, Chan TA, Beal K, Bishop AJ, Baker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, Weller M, Holland EC, Hambardzumyan D. Corticosteroids compromise survival in glioblastoma. Brain 2016; 139: 1458 - 1471

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M. Bevacizumab plus Irinotecan versus Temozolomide in newly diagnosed 06-Methylguanine-DNA Methyltransferase nonmethylated Glioblastoma: The randomized GLARIUS Trail. J Clin Oncol. 2016; 34: 1611 - 1619

Korfel A, Schlegel U, Herrlinger U, Dreyerling M, Schmidt C, von Baumgarten L, Pezzutto A, Grobosch T, Kebir S, Thiel E, Martus P, Kiewe P. Phase II Trial of Temsirolimus for relapsed/refractory Primary CNS Lymphoma. J Clin Oncol. 2016; 34: 1757 - 1763

Latzer P, Schlegel U, Theiss C. Morphological changes of cortical and hippocampall Neurons after treatment with VEGF and Bevacizumab. CNS Neurosci Ther. 2016; 22: 440 - 450

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR Trial. Neuro Oncol. 2016;18: 549 - 556

Baraniskin A, Zaslava E, Nöpel-Dünnebacke S, Ahle G, Seidel S, Schlegel U, Schmiegel W, Hahn S, Schroers R. Circulating U2 small nuclear RNA fragments as a novel diagnostic bi-omarker for primary central nervous system lymphoma. Neuro Oncol. 2016,18: 361 - 367

Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Rudà R, Schlegel U, Siegal T, Soussain C, Abacioglu U, Cassoux N, Deckert M, Dirven CM, Ferreri AJ, Graus F, Henriksson R, Herrlinger U, TAphoorn M, Soffietti R, Weller M; European Association for Neuro-Oncology Task Force on Primary CNS Lymphoma. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16: e322 - 332

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H. Reifenberger G. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol. 2015;129: 679 - 693

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabe MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W. MGMT promotor methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin Cancer Res. 2015;21: 2057 - 2064

Westphal M, Heese O, Steinbach JP, Schnell O, Schackert G, Mehdorn M, Schulz D, Simon M, Schlegel U, Senft C, Geletneky K, Braun C, Hartung JG, Reuter D, Metz MW, Bach F, Pietsch T. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer 2015;51: 522 - 532

Reifenberger G, Weber RG, Riehmer V, Kaulich K, Willscher E, Wirth H, Gietzelt J, Hentschel B, Westphal M, Simon M, Schackert G, Schramm J, Matschke J, Sabel MC, Gramatzki D, Felsberg J, Hartmann C, Steinbach JP, Schlegel U, Wick W, Radlwimmer B, Pietsch T, Tonn JC, von Deimling A, Binder H, Weller M, Loeffler M; for the German Glioma Network. Molecular characterization of long-term survivors of glioblastoma using genome-and transcriptome-wide profiling. Int J Cancer 2014;135: 1822 - 1831

Eisele G, Wick A, Eisele AC, Clément PM, Tonn J, Tabatabai G, Ochsenbein A, Schlegel U, Neyns B, Krex D, Simon M, Nikkhah G, Picard M, Stupp R, Wick W, Weller M. Cilengitide treatment of newly diagnoses glioblastoma patients does not alter patterns of progression. J Neurooncol 2014;117: 141 - 145

Heese O, Vogeler E, Martens T, Schnell O, Tonn JC, Simon M, Schramm J, Krex D, Schackert G, Reithmeier T, Nikkah G, Sabel M, Steiger HJ, Schlegel U, Löffler M, Weller M, Westphal M; for the German Glioma Network. End-of-life caregiver`s perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. Neuro Oncol. 2013;15: 1251 - 1256

Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel U, Rogowski S, Fu R, Dósa E, Illerhaus G, Kraemer DF, Muldoon LL, Calabrese P, Hedrick N, Tyson RM, Jahnke K, Maron LM, Butler RW, Neuwelt EA. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 2013;81: 84 - 92

Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol. 2013;9: 317 -327

Semmler A, Garbe S, Moskau S, Fisch C, Eter N, Schlegel U, Linnebank M. An efficient method for fractionated whole rodent brain radiation. Neurol Res. 2013;35: 355 - 359

Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz CW, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L. Phase II study of CNS-directed chemotherapy uncluding high-dose chemotherapy with autologus stemm cell transplantation for CNS relapse of aggressive lymphomas. Haematologica 2013;98: 364 - 370

Linnnebank M, Moskau S, Kowoll A, Semmler A, Bangard C, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Schmidt-Wolf IG, Pels H, Schlegel U. Association of transcobalamin c. 776>G with overall survival in patients with primary central nervous system lymphoma. Br J Cancer. 2012;107: 1840 - 1843

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixenberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society. Pels H, Schlegel U, Herrlinger U, Pietsch T, Schramm J, Krex D, Schackert G, Rapp M, Wille C, Blümcke I, Diener HC, Bähr O, Rieger J, Franz K, Seifer V, Plate KH, Wille C, Westphal M, Heidenreich F, Wiese B, Bremer M, Nakamura M, v Deimling A, Klein AC, Pfennig P, Schemmer D, Wick A, Oertel J, Kortmann R, Conrad J, Wiewrodt D, Schmieder K, Wenz F, Bogdahn U, Hau P, Bamberg M, Melms A, Döhner H, Happold C, Zaugg K. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13: 707 - 715

Kuhnhenn J, Kowalski T, Steenken S, Ostermann K, Schlegel U. Procarbazine, carmustine and vincristine (PBV) for chemotherapy pre-treates patients with recurrent glioblastoma: a single-institution analysis. J Neurooncol. 2012;109: 433 - 438

Baraniskin A, Kuhnhenn J, Schlegel U, Schmiegel W, Hahn S, Schroers R. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J Neurooncol. 2012;109: 239 - 244

Baraniskin A, Kuhnhenn J, Schlegel U, Magnhnouj A, Zöllner H, Schmiegel W, Hahn S, Schroers R. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro Oncol. 2012;14: 29 - 33

Deckert M, Engert A, Brück W, Ferreri AJ, Finke J, Illerhaus G, Klapper W, Korfel A, Küppers R, Maarouf M, Montesinos-Rongen M, Paulus W, Schlegel U, Lassmann H, Wiestler OD, Siebert R, Deangelis LM. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia 2011;25: 1797 - 1807

Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117: 3140 - 3146

Hinkerohe D, Wolfkühler D, Haghikia A, Meier C, Faustmann PM, Schlegel U. Dexamethasone differentially regulates functional membrane properties in glioma cell lines and primary CNS lymphoma. J Neurooncol. 2011;103: 479 - 489

Ostermann K, Pels H, Kowoll A, Kuhnhenn J, Schlegel U. Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma. J Neurooncol. 2011;103: 635 - 640

Schroers R, Baraniskin A, Heute C, Vorgerd M, Brunn A, Kuhnhenn J, Kowoll A, Alekseyev A, Schmiegel W, Schlegel U, Deckert M, Pels H. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur J Haematol. 2010;85: 520 -528

Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, Schmiegel W, Schlegel U, Pels H. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol. 2010;85: 236 - 242

Fliessbach K, Rogowski S, Hoppe C, Sabel M, Goeppert M, Helmstaedter C, Calabrese G, Schackert G, Tonn JC, Simon M, Schlegel U. Computer-based assessment of cognitive functions in brain tumor patients. J Neurooncol. 2010;100: 427 - 437

Stupp R, Hegi M, Neyns B, Goldbrunner R, Schlegel U, Clement P, Grabenbauer G, Ochsenbein A, Simon M, Dietrich P, Pietsch T, Hicking C, Tonn J, Diserens A, Pica A, Hermission M, Krueger S, Picard M, Weller M. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28: 2712 - 2718

Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, Schlegel U. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous sysem lymphoma. Ann Neurol. 2010;67: 182 -189

Grzendowski M, Wolter M, Riemenschneider MJ, Knobbe CB, Schlegel U, Meyer HE, Reifenberger G, Stühler K. Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. Neuro Oncol.2010;12: 243 - 256

Pels H, Juergens A, Schirgens I, Glasmacher A, Schulz H, Engert A, Schackert G, Reichmann H, Kroschinsky F, Vogt-Schaden M, Egerer G, Bode U, Deckert M, Fimmers R, Urbach H, Schmidt-Wolf IG, Schlegel U. Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol.2010;12: 720 - 724